Agouron's Good News for Biotech
Using its red-hot shares to buy assets, Warner-Lambert is acquiring Agouron, a company with higher growth but the same P/E multiple--and thus bringing with it no dilution. Other major drug companies, enjoying similarly high valued shares largely on account of their size, not their pipelines, should consider the same cost-effective strategy.
You may also be interested in...
The US agency has released a document explaining what COVID-19 testing supplies may be substituted.
Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.
AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.